Cereblon and IRF4 Variants Affect Risk and Response to Treatment in Multiple Myeloma

Aleksandra Butrym1 · Piotr Łacina2 · Justyna Rybka3 · Monika Chaszczewska-Markowska2 · Grzegorz Mazur4 · Katarzyna Bogunia-Kubik2,4

Received: 29 June 2016 / Accepted: 24 October 2016 / Published online: 12 January 2017 © The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract Multiple myeloma (MM) is a plasma-cell malignancy derived from an early precursor of the B-cell lineage characterised by bone-marrow infiltration, lytic bone lesions, and the presence of a monoclonal protein in serum and/or urine. Interferon regulatory factor 4 (IRF4) is a critical transcriptional regulator in B-cell development and function that is required during immune response for lymphocyte activation and the generation of immunoglobulin-secreting plasma cells. Immunomodulatory drugs, derivatives of thalidomide, are commonly used in therapy against MM. They are known to target a protein called cereblon (CRBN); however, the exact mechanism remains unknown. The present study aimed to assess the association of two (rs12203592 and rs872071) polymorphisms within the IRF4 gene and two (rs711613 and rs1045433) in the CRBN gene with MM susceptibility, progression, and response to treatment. For this purpose, 144 MM patients and 126 healthy individuals were genotyped for the IRF4 and CRBN alleles. The presence of the IRF4 (rs872071) G allele was more frequently detected in patients than healthy individuals (OR 1.78; \( P = 0.034 \)), and this relationship was especially pronounced in women (OR 2.83; \( P = 0.012 \)). The CRBN (rs711613) A allele-carriers were better responders to the treatment (\( P = 0.012 \)), in particular to thalidomide including therapy (\( P = 0.023 \)). These results underline the prognostic significance of the IRF4 and CRBN polymorphisms in patients with MM.

Keywords Cereblon · Interferon regulatory factor 4 · Single nucleotide polymorphisms · Multiple myeloma · Disease susceptibility · Stage of the disease · Response to treatment

Introduction

Multiple myeloma (MM) is a malignancy characterised by the presence of malignant plasma cells in bone marrow, impaired immunoglobulin production, and the presence of a monoclonal protein in serum and/or urine. It is the second most frequent hematological disease and results in severe bone lesions, renal insufficiency, anaemia, and hypercalcaemia (Raab et al. 2009).

Immunomodulatory drugs (IMiDs) are a group of drugs including thalidomide and its derivatives (lenalidomide and pomalidomide) that are commonly used in therapy against MM. Their mechanism of action remained unknown until recently, when cereblon (CRBN) found to be the target of thalidomide (Chang and Stewart 2011; Huang et al. 2014). Cereblon was originally thought to have a role in cerebral development (hence its name, with -lon standing for the Lon domain) (Higgins et al. 2004). As a target gene of thalidomide, cereblon most likely mediates all known thalidomide effects, such as cell cycle arrest in myeloma...
cells and teratogenicity in embryos (Ito et al. 2010; Lopez-Girona et al. 2012).

Effects of IMiDs in MM cells are pleiotropic, causing, among others, decrease in expression of anti-apoptotic factor Bcl2, G0/G1 arrest through p21\(^{\text{WAF1}}\) up-regulation, and down-regulation of interferon regulatory factor 4 (IRF4) (Lopez-Girona et al. 2012). IRF4 is a member of the IRF family of proteins that is crucial in the development of the immune system. IRF4 plays multiple roles in maturation of blood cells, particularly in the process of B-cell development, including plasma cell differentiation (Klein et al. 2006). IRF4 is required for normal differentiation of B cells into plasma cells (Klein et al. 2006), but it has also been proved to exert major influence on both healthy plasma cells and malignant ones. In myeloma cells, IRF4 is known to up-regulate over 100 genes (as compared to primary plasma cells), and many amongst them are associated with cellular growth and survival, like MYC. Because of pleiotropic effects of IRF4 in myeloma cells, multiple myeloma is said to be “addicted” to IRF4, with lower expression thereof severely hurting myeloma cells (Shaffer et al. 2008).

The aim of this study was to assess relationship of four selected single nucleotide polymorphisms (SNPs) in IRF4 and CRBN genes with risk for disease, response to treatment and other prognostic factors in MM. It is a continuation of our previous study, where we investigated two SNPs in the gene coding for β-catenin and one (rs121918368C > T) within the cereblon encoding gene (Butrym et al. 2015).

The latter one was located within the coding region but we did not observe the presence of its polymorphic variant in our Polish (MM patients and healthy controls) population. Currently, two further SNPs within the CRBN gene were selected that may potentially be involved in the control of the CRBN gene expression. Our previous studies showed that substitutions within the untranslated regions (UTR) may be associated with the disease (Butrym et al. 2015). Therefore, the substitutions chosen, rs711613A > G and rs1045433A > G, are located in non-coding regions (intron 1 and 3′UTR, respectively) of the CRBN gene, itself located in chromosome 3, at the location 3p26.2. They were never studied before and any effects of those variants on cereblon are unknown.

The IRF4 encoding gene is located in the short arm of chromosome 6, at 6p23-p25 (Do et al. 2010; Grossman et al. 1996). Two known SNPs of this gene, rs12203592 and rs872071, were subject of this study. rs12203592 is a C > T SNP located in intron 4 and known to affect pigmentation; it is considered as a risk factor in skin cancers (Han et al. 2011). Its T-variant is known to be associated with lower expression levels of the IRF4 gene (Han et al. 2011), which means that it could potentially affect not only pigmentation-related diseases, but also other ones, such as multiple myeloma.

The other SNP investigated in this study is rs872071. It is a A > G substitution located in the 3′UTR. It has been shown earlier that this SNP was a risk factor of two haematological diseases, chronic lymphocytic leukemia and Hodgkin lymphoma. In both cases, the G allele was more common in patients than in healthy controls (Brod-erick et al. 2009; Di Bernardo et al. 2008). It was also reported that the G allele is associated with lower expression of IRF4 (Di Bernardo et al. 2008). Association of the rs872071 polymorphism with risk for multiple myeloma has been investigated in a study on a group of British Caucasian patients, but no such association was found (Pratt et al. 2010).

**Materials and Methods**

**Patients and Controls**

For this study, we used a group of 144 Polish MM patients who were already studied in our previous work about CRBN and CTNNB1 SNPs. Detailed information available in manuscript of Butrym et al. (2015). In addition, 126 healthy individuals of both sexes served as a control group for the IRF4 SNPs, while 237 healthy individuals served as a control group for the CRBN SNPs.

**Genotyping**

DNA was extracted from samples of peripheral blood taken on EDTA using Maxwell 16 Blood DNA Purification Kit (Promega Corp., USA) or silica membranes (Qiagen, Germany) following the recommendations of the manufacturers. Determination of the IRF4 and CRBN polymorphisms was carried out by the LightSNiP typing assay (TIB-MolBiol, Berlin, Germany) on a LightCycler 480 Real-Time PCR system (Roche Applied Science, Mannheim, Germany). Amplifications were performed following the recommendation of the manufacturer.

**Statistical Analysis**

Fisher’s exact test was used to test the null hypothesis that there is no difference between allele and genotype frequencies between patients and controls. The odd’s ratio (OR) was calculated by Haldane’s modification of Woolf’s method. In addition, the Statistical Package for Social Scientists (SPSS, SYSTAT 10) was used for multivariate logistic regression analysis. Probability values <0.05 were considered statistically significant, and those between 0.05 and 0.10 as indicative of a trend. All genotypes were tested for deviations from Hardy–Weinberg equilibrium using the \( \chi^2 \) test.
Results

CRBN Polymorphisms and Response to Treatment with Thalidomide

Of the 144 patients genotyped, we had data about response to treatment for 131 individuals. The response rate was 107/131, with the rest of patients progressing or having stable disease after treatment.

Analysis of gene and allele frequencies showed no statistically significant differences between patients and controls in the case of either of the two CRBN polymorphisms. We observed, however, major differences regarding response to treatment. The rs711613 A allele was more common in patients who had a complete or partial remission after first-line therapy as compared to patients in whom the disease either remained stable or progressed \( (P = 0.012) \). Multivariate analyses were employed to assess the independent association of the CRBN gene polymorphism with the treatment outcome. Age of patients, sex and stage of the disease assessed according to the Duire-Salomon criteria and International Staging System (ISS) score were also considered in these analyses. The analyses confirmed the effect of the rs711613 A variant as a protective factor associated with better response to treatment \( (OR = 0.306, 95\% CI 0.125–0.753; P = 0.010) \), while more advanced disease (ISS score: 3) appeared to be a risk factor of unfavourable prognosis \( (OR = 4.100, 95\% CI 1.586–10.598; P = 0.004) \). Similar relationships were observed when ISS score >II was considered (individual data not shown).

The association of the CRBN rs711613 A allele was also seen in a group of patients who were treated with thalidomide, alone or in combination with other drugs \( (P = 0.023) \), but was not statistically significant in a subgroup of patients treated with cyclophosphamide–thalidomide–dexamethasone (CTD; \( P = 0.086) \).

We also noticed that rs1045433 G allele tended to be more common in patients with complete or partial response after any first-line therapy and therapy with first-line therapy involving thalidomide, but those two associations were not statistically significant \( (P = 0.081 \) and \( P = 0.092, \) respectively).

Furthermore, we have also found that the rs711613 G allele is much more common in patients in stages I–II (according to the Durie–Salomon criteria) than patients who are in stage III \( (P = 0.005) \).

Associations of IRF4 rs872071 with Disease Susceptibility and Progression

The comparison of gene and allele frequencies between controls and cases showed that the rs872071 G allele was more frequent in cases compared with controls \( (0.504 \) and \( 0.397) \), with odds ratio \( 1.73 (95\% \text{ CI } 1.02–2.94; P = 0.046) \). Stratifying cases and controls according to gender revealed that the increase of the G allele in cases compared with controls was even more pronounced in women, with the OR \( 2.73 (95\% \text{ CI } 1.24–6.01; P = 0.013) \), while no statistically significant association was observed in men \( (OR = 1.17, 95\% \text{ CI } 0.57–2.41; P = 0.714) \). Moreover, the GG genotype alone was also found to be more common in cases \( (24.6\%) \) compared with controls \( (9.5\%) \). The odds ratio for this association was \( 3.11 (95\% \text{ CI } 1.14–8.47; P = 0.037) \).

In addition, an association with progression of the disease was observed. The rs872071 G allele was more common in MM patients in stages I–II (according to Durie–Salomon staging system) compared with patients in the final stage III: among the patients in stages I–II 80.8% carried the G allele, while only 63.3% in stage III \( (OR = 2.44, 95\% \text{ CI } 1.09–5.48; P = 0.038) \). Adjusting for the duration of disease resulted in a slightly different odds ratio \( (OR_{adj} = 2.30, 95\% \text{ CI } 1.01–5.24) \).

Stratifying all the patients into two groups according to the duration of disease revealed that the rs872071 G allele was more commonly found in patients suffering from MM longer than 3 years compared with patients suffering there from for 3 years or shorter. In the former group, 85.4% were carriers of the G allele, while in the latter, only 68.7% \( (OR = 2.67, 95\% \text{ CI } 1.06–6.74; P = 0.038) \). The odds ratio and 95% confidence intervals changed after adjusting for age: \( OR = 2.54, 95\% \text{ CI } 0.98–6.59) \.

Lack of Significant Relationships with the rs12203592 SNP

No statistically significant associations with either risk, progression or duration of disease were observed with the rs12203592 polymorphism. Furthermore, no association with response to treatment was found in either of the two studied SNPs.

Detailed Information on Genotypes

Detailed data for genotypes of all four SNPs in both patients and controls are presented in Table 1 and will be published in MultiGenBank—the immunogenetic database of the Polish population accessible under http://multigenbank.pl/en.

Discussion

In our study, we demonstrated that the two SNPs in the non-coding regions of the CRBN gene, rs711613 and rs1045433, are associated with different response to treatment in general and to treatment with thalidomide in
As the SNPs in question do not result in different protein structure, it is possible that they exert their influence by modulating expression of cereblon. It has already been shown that cereblon levels do influence outcome of IMiD-based therapy and patients with lenalidomide resistance have decreased levels of it. In addition, CRBN expression was reported to not affect response to other anti-myeloma agents, which may explain why we found no association between the two CRBN polymorphisms and response to CTD therapy (including thalidomide and two other agents) (Schuster et al. 2014).

Regarding IRF4, the SNP we have investigated, rs872071 A → G, is located in the 3'UTR of the gene and has been associated with increased risk for chronic lymphocytic leukemia and Hodgkin lymphoma, suggesting that it might also be a risk factor in other haematological diseases. It affects expression levels of IRF4, as the G variant has been shown by Di Bernardo et al. to decrease levels of IRF4 mRNA (Di Bernardo et al. 2008; Broderick et al. 2009). Earlier study by Pratt et al. (2010) supplied no evidence for an association between this SNP and risk for multiple myeloma. However, because myeloma cells are derived from plasma cells, this model would suggest a different result than the one we and Pratt et al. (2010) observed, i.e., lower IRF4 levels in people with G allele would decrease the number of plasma cells and thus lower the risk for multiple myeloma, instead of increasing it. Because of this, we concluded that there must be other factor(s) involved that we did not consider in our study. We conducted a thorough research of the available literature related to IRF4 and based thereon, we propose a different model for the rs872071 G as a risk factor in MM, based on the interaction of IRF4 with the transcriptional repressor B lymphocyte-induced maturation protein 1 (BLIMP-1). BLIMP-1 is up-regulated by IRF4 and is known to repress expression of many genes associated with growth in B cells, like MYC (Sciammas et al. 2006; Shaffer et al. 2008). It is expressed in plasma cells to stop MYC expression, which is necessary during B-cell activation. This mechanism is somehow abrogated in myeloma cells. As a result, MYC is overexpressed following the translocations of its gene, which in turn induces overexpression of

### Table 1: Genotype frequencies for the polymorphisms under study

| Gene | Polymorphism | Genotypes   | AA (%) | AG (%) | GG (%) |
|------|--------------|-------------|--------|--------|--------|
| CRBN | rs711613A > G | MM          | 11.0   | 46.7   | 42.3   |
|      |              | Controls    | 11.5   | 46.6   | 41.9   |
|      | rs1045433A > G | MM         | 66.4   | 30.7   | 2.9    |
|      |              | Controls    | 64.2   | 31.5   | 4.3    |
| IRF4 | rs872071A > G | MM          | 25.6   | 48.2   | 26.3*  |
|      |              | Controls    | 37.3   | 46.0   | 16.7*  |

* This SNP is a risk factor in a recessive model, OR 1.73, P = 0.046 (P = 0.013 in women only)
IRF4, thus forming a loop which helps the myeloma cells survive and grow (Shaffer et al. 2008). Reduced expression of IRF4 in people carrying the rs872071 G allele should lead to reduced expression of BLIMP-1, which, given the function of BLIMP-1 as a MYC repressor, could help in abnormal growth of MYC expression during the formation of multiple myeloma (Fig. 1).

Furthermore, we have also found that the rs872071 G allele is more frequent in MM patients in stages I–II of the disease than in patients in stage III (according to Durie-Salmon staging system), and is thus associated with slower progression of disease. This association was still observed after the results had been adjusted for duration of disease. These findings are in line with previous observations showing that mature myeloma cells are “addicted” to IRF4, which controls expression of a host of different genes associated with growth and survival, among them STAG2, CDK6, and MYC (Shaffer et al. 2008). Lower expression of IRF4 in people the allele apparently results in lower expression of all its target genes necessary for tumor growth, thus slowing its progression down.

We have also ruled out the rs12203592 SNP as a potential risk factor for multiple myeloma. It is a known risk factor for skin cancer and has been known to influence IRF4 expression (Do et al. 2010). It is possible that the effects of this polymorphism occur in conjunction with unknown tissue-specific transcriptional factors.

In summary, our present study contributes to the reports on genetic factors in MM. Obviously, these observations warrant further, more extended study.

**Fig. 1** Role of IRF4 expression in myeloma cells. IRF4 and MYC form an auto-regulatory loop, with the former up-regulating the latter and vice versa. This loop is required during the B-cell activation, but is later abrogated in mature plasma cells through expression of BLIMP-1, which represses MYC. In myeloma cells, this mechanism of repression is somehow inactivated, causing the IRF4-MYC loop to spiral of control, facilitating tumor growth. Increased levels of IRF4 (as in people with rs872071G allele) could impede the IRF4-MYC loop, thus slowing down the progression of the disease. On the other hand, increased levels of IRF4 would result in lower levels of BLIMP-1, which could help establish the IRF4-MYC loop during plasma cell formation, thus helping in tumorigenesis.

**Acknowledgements** This work was supported by statutory activity of Wroclaw Medical University (Project No. ST-370). The authors thank the Regional Centre of Transfusion Medicine and Blood Bank in Wroclaw for providing control samples.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

Broderick P, Cunningham D, Vijayakrishnan J et al (2009) IRF4 polymorphism rs872071 and risk of Hodgkin lymphoma. Br J Haematol 148:413–415

Butrym A, Rybka J, Lacina P et al (2015) Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment. Leuk Res 39:1462–1466

Chang XB, Stewart AK (2011) What is the functional role of the thalidomide binding protein cereblon? Int J Biochem Mol Biol 2:287–294

Di Bernardo MC, Crowther-Swanepoel CD, Broderick P et al (2008) A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet 40:1204–1210

Do TN, Ucisik-Akkaya E, Davis CF et al (2010) An intronic polymorphism of IRF4 gene influences gene transcription in vitro and shows a risk association with childhood acute lymphoblastic leukemia in males. Biochim Biophys Acta 1802:292–300

Grossman A, Mittrucker HW, Nicholl J et al (1996) Cloning of human lymphocyte-specific interferon regulatory factor (hLSIRF/ hIRF4) and mapping of the gene to 6p23-p25. Genomics 37:229–233
Han J, Qureshi AA, Nan H et al (2011) A germline variant in the interferon regulatory factor 4 gene as a novel skin cancer risk locus. Cancer Res 71:1533–1539
Higgins JJ, Pucilowska J, Lombardi RQ et al (2004) A mutation in a novel ATP-dependent Lon protease gene in a kindred with mild mental retardation. Neurology 63:1927–1931
Huang SY, Lin CW, Lin HH et al (2014) Expression of cereblon protein assessed by immunohistochemical staining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma. Ann Hematol 93:1371–1380
Ito T, Ando H, Suzuki T et al (2010) Identification of a primary target of thalidomide teratogenicity. Science 327:1345–1350
Klein U, Casola S, Cattoretti G et al (2006) Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol 7:773–782
Lopez-Girona A, Mendy D, Ito T et al (2012) Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26:2326–2335
Mazur G, Bogunia-Kubik K, Wróbel T et al (2005) IL-6 and IL-10 promoter gene polymorphisms do not associate with the susceptibility for multiple myeloma. Immunol Lett 96:241–246
Mazur G, Gębura K, Gieryng A et al (2013) The CXCL12-3'A allele plays a favourable role in patients with multiple myeloma. Cytokine 64:422–426
Pratt G, Frenton JA, Allsup D et al (2010) A polymorphism in the 3' UTR of IRF4 linked to susceptibility and pathogenesis in chronic lymphocytic leukaemia and Hodgkin lymphoma has limited impact in multiple myeloma. Br J Haematol 150:371–373
Raab MS, Poddar K, Breitkreutz I et al (2009) Multiple myeloma. Lancet 374:324–339
Schuster SR, Kortuem KM, Zhu YX et al (2014) The clinical significance of cereblon expression in multiple myeloma. Leuk Res 38:23–28
Sciammas R, Shaffer AL, Schatz JH et al (2006) Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity 25:225–236
Shaffer AL, Emre NC, Lamy L et al (2008) IRF4 addiction in multiple myeloma. Nature 454:226–231